Caplin Point Laboratories Ltd Stock NSE India S.E.
Equities
INE475E01018
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- INR | - |
Apr. 16 | Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution | MT |
Mar. 28 | Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication | MT |
Sales 2024 * | 16.92B 203M | Sales 2025 * | 19.11B 229M | Capitalization | 103B 1.23B |
---|---|---|---|---|---|
Net income 2024 * | 4.57B 54.82M | Net income 2025 * | 4.17B 50.04M | EV / Sales 2024 * | 6.06 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.37 x |
P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
20.9
x | Employees | - |
Yield 2024 * |
0.23% | Yield 2025 * |
0.25% | Free-Float | 25.33% |
Latest transcript on Caplin Point Laboratories Ltd
Managers | Title | Age | Since |
---|---|---|---|
Sridhar Ganesan
CEO | Chief Executive Officer | 69 | 15-03-27 |
D. Muralidharan
DFI | Director of Finance/CFO | - | 16-02-18 |
Anto V.
ADM | Chief Administrative Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | - | |
Chief Operating Officer | - | 10-11-30 | |
Sridhar Ganesan
CEO | Chief Executive Officer | 69 | 15-03-27 |
1st Jan change | Capi. | |
---|---|---|
+19.62% | 43.78B | |
+20.44% | 21.89B | |
+10.86% | 14.45B | |
+13.07% | 13.63B | |
+37.46% | 11.49B | |
-8.59% | 6.85B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.06B |